CurrentCignaPolicy N/A

Drug Quantity Management Policy - Topical Corticosteroids (Triamcinolone 0.147 mg/g spray)

Defines drug quantity management limits and approval criteria for triamcinolone 0.147 mg/g topical spray (Kenalog and generics) for Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyDrug Quantity Management Policy - Topical Corticosteroids (Triamcinolone 0.147 mg/g spray)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateDec 6, 2024

Key ActionLimit initial treatment to 2 consecutive weeks; approve a one-time override for additional quantities only if the patient uses the product for an FDA‑approved indication and meets the listed criteria.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

63 gpackage size

100 gpackage size

126 gretail max (63g)

378 ghome max (63g)

100 gretail max (100g)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Additional quantity approval

Approval of additional quantities is recommended if the patient is using the product for an FDA-approved indication and meets the following:

63g container override: If the patient's condition has not sufficiently improved after the initial 2 weeks of treatment with triamcinolone spray, approve a one-time override for an additional quantity not to exceed 126 grams at retail or 378 grams at home delivery to allow for a total of 4 consecutive weeks of therapy at retail or 12 consecutive weeks of therapy at home delivery.retail<=126 g; home<=378 g

one-time override to extend therapy

100g container override: If the patient's condition has not sufficiently improved after the initial 2 weeks of treatment with triamcinolone spray, approve a one-time override for an additional quantity not to exceed 100 grams at retail or 300 grams at home delivery to allow for a total of 4 consecutive weeks of therapy at retail or 12 consecutive weeks of therapy at home delivery.retail<=100 g; home<=300 g

one-time override to extend therapy

No overrides are recommended for use in any compounded formulations.

Provider Actions and Enforcement

Billing Rule

Quantity limit enforcement and approvals

Retail and home delivery drug quantity limits are enforced at point of service. Retail maximums per 30 days: Kenalog 63 g — 126 grams; generic 100 g — 100 grams. Home delivery maximums per 90 days: Kenalog 63 g — 378 grams; generic 100 g — 300 grams. If a request exceeds these limits, coverage is determined by clinical criteria below and prior authorization or an override may be required.

Kenalog (63 g can): Retail max per 30 days = 126 g; Home delivery max per 90 days = 378 g
Triamcinolone acetonide 0.147 mg/g topical aerosol (100 g can): Retail max per 30 days = 100 g; Home delivery max per 90 days = 300 g

Note

Initial treatment duration

Initial treatment with triamcinolone 0.147 mg/g spray should be limited to 2 consecutive weeks. Treatment beyond 2 consecutive weeks may be considered when there is inadequate improvement; approvals for additional quantities are provided as one-time overrides per the criteria.

Definitions

Triamcinolone 0.147 mg/g spray

Drug descriptionTriamcinolone 0.147 mg/g topical spray — a high‑potency topical corticosteroid aerosol for inflammatory and pruritic manifestations of corticosteroid‑responsive dermatoses (e.g., plaque psoriasis, atopic dermatitis).

Potency / strength0.147 mg triamcinolone acetonide per gram of spray (0.147 mg/g).

Available can sizes63 g and 100 g aerosol cans.

Application dosing noteMay be applied three to four times daily; a 2‑second application covers ~one hand and delivers up to 0.2 mg triamcinolone acetonide. Initial treatment should be limited to 2 consecutive weeks; extension beyond 2 weeks may be indicated if no improvement.

Triamcinolone 0.147 mg/g topical spray is a high-potency topical corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid‑responsive dermatoses (for example, plaque psoriasis and atopic dermatitis). Typical application is three to four times daily, and initial treatment is generally limited to 2 consecutive weeks, with extension considered only if there is insufficient improvement. The product is available as aerosol cans in 63 g and 100 g sizes; a 2‑second application covers about a hand and delivers up to 0.2 mg triamcinolone acetonide per application.

Initial Therapy Criteria

Initial therapy

Initial dosing and duration guidance

Initial treatment: Apply 3-4 times daily; limit initial treatment to 2 consecutive weeks; treatment beyond 2 weeks may be indicated if there is no observed improvement.2 weeks

Quantity Limits

Kenalog (63 g can) — retail

ProductKenalog (triamcinolone acetonide 0.147 mg/g topical aerosol), package size 63 g.

Retail maximum126 grams per 30 days.

PurposeQuantity limit enforces initial and approved one‑time override amounts to prevent stockpiling/overuse.

Kenalog (63 g can) — home delivery

ProductKenalog (triamcinolone acetonide 0.147 mg/g topical aerosol), package size 63 g — home delivery.

Home delivery maximum378 grams per 90 days.

Note

Policy Summary

PayerCigna

PolicyDrug Quantity Management Policy - Topical Corticosteroids (Triamcinolone 0.147 mg/g spray)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateDec 6, 2024

SourceLink

On This Page

Limit initial treatment duration to 2 consecutive weeks
Approvals for extended therapy are single overrides to permit up to 4 consecutive weeks (retail) or 12 consecutive weeks (home delivery) when criteria are met

Documentation Required

Documentation and coverage determination context

Coverage determinations must consider the terms of the applicable benefit plan document, any applicable laws/regulations, relevant collateral materials (including this policy), and the specific facts of the case. Medical Directors retain discretion to make individual determinations. Documentation supporting FDA‑approved indication and clinical response should be submitted to justify overrides or exceptions.

Consider the member's benefit plan language (e.g., EOC, SPD) — plan terms control in case of conflict
Apply relevant state/federal mandates and collateral materials (coverage policies, vendor guidelines)
Provide documentation of diagnosis, prior treatment, and lack of improvement after initial 2 weeks when requesting additional quantity

Denial Risk

Drug quantity rule noncompliance

If the Drug Quantity Management rule is not met at the point of service, coverage will be determined by the criteria in this policy. All approvals are provided for the duration specified in the criteria and are subject to clinical review.

Noncompliant requests routed to clinical review and judged against policy criteria
Approvals issued only for durations noted (one-time overrides to allow up to specified total therapy weeks)

Home delivery limits allow longer duration (up to 12 consecutive weeks when approved) compared with retail.

Triamcinolone generic (100 g can) — retail

ProductTriamcinolone generic 0.147 mg/g topical aerosol, package size 100 g.

Retail maximum100 grams per 30 days.

Override allowanceOne‑time override may be approved (if condition not improved after initial 2 weeks) for additional quantity up to the retail maximum to allow a total of 4 consecutive weeks at retail.

Triamcinolone generic (100 g can) — home delivery

ProductTriamcinolone generic 0.147 mg/g topical aerosol, package size 100 g — home delivery.

Home delivery maximum300 grams per 90 days.

Override allowanceOne‑time override may be approved (if condition not improved after initial 2 weeks) for additional quantity up to the home delivery maximum to allow a total of 12 consecutive weeks at home delivery.